Abstract:Key PointsAsthma and chronic obstructive pulmonary disease (COPD) are both associated with chronic inflammation of the respiratory tract and with increased inflammation during disease exacerbations. However, the inflammatory pattern differs between these two diseases.The inflammation in asthma mainly involves the proximal airways, whereas in COPD inflammation mainly occurs in the peripheral airways and the lung parenchyma.Asthma is typically characterized by activated mucosal mast cells, an infiltration of eosinophils and activated T helper 2 (TH2) cells, whereas in COPD macrophages, neutrophils and type 1 cytotoxic T (TC1) cells predominate.These distinct patterns reflect differences in the mechanisms that drive the inflammatory response, with responses being driven by allergens in asthma and by chronic inhaled irritants, such as cigarette smoke, in COPD.The pattern of inflammatory mediators produced also differs between the two diseases. In asthma, there are increased levels of mediators, such as histamine and cysteinyl leukotrienes, that cause bronchoconstriction and of TH2-type cytokines (such as interleukin-4 (IL-4), IL-5, IL-9 and IL-13), which orchestrate the inflammatory response through activation of the transcription factors GATA3 (GATA-binding protein 3) and NFAT (nuclear factor of activated T cells). By contrast, in COPD, there is an increase in the levels of nonspecific cytokines, such as IL-6 and tumour-necrosis factor, and chemokines that are associated with monocytic and neutrophilic inflammation (such as CXCL8, CXCL1 and CCL2).In severe asthma and asthmatics who smoke, the inflammatory pattern changes to become more similar to that seen in COPD, with more involvement of the peripheral airways, increased infiltration of neutrophils and CD8+ T cells.Differences in inflammatory patterns affect the response of these two diseases to therapy. Mild asthma is very responsive to corticosteroids, as these drugs suppress the multiple inflammatory genes that are activated through recruitment of the enzyme histone deacetylase 2 (HDAC2). However, in COPD and severe asthma, corticosteroids fail to suppress inflammation owing to a reduction in HDAC2 activity and expression. In the future, specific immunosuppressants may be a useful approach to therapy.

Asthma: pathology and pathophysiology.

The pathophysiology of airway dysfunction

Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons

Current Understanding of Asthma Pathogenesis and Biomarkers

New insights into asthma pathogenesis and treatment

Current concepts in clinical therapeutics: asthma

Current Understanding on Molecular Perspectives

Immunology of asthma and chronic obstructive pulmonary disease

Approaches to studying the pathogenesis of asthma

EVOLUTION OF UNDERSTANDING THE ROLE OF CHRONIC INFLAMMATION AS A KEY ELEMENT IN ASTHMA PATHOGENESIS

Understanding the immunology of asthma: Pathophysiology, biomarkers, and treatments for asthma endotypes

Psychopathology in Asthma Patients: Analysis of Demographic and Clinical Associations

Asthma Inception: Epidemiologic Risk Factors and Natural History Across the Life Course

Immunological factors, important players in the development of asthma

Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease

Pathological Roles of Neutrophil-Mediated Inflammation in Asthma and Its Potential for Therapy As a Target

Advances and recent developments in asthma in 2020

Bronchial Asthma, Airway Remodeling and Lung Fibrosis as Successive Steps of One Process

Eosinophilic Airway Diseases: From Pathophysiological Mechanisms to Clinical Practice